查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471980

子宫颈癌治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按类型、产品、最终用户和地理位置

Cervical Cancer Treatment Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Product, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

子宫颈癌治疗市场预计将从2022年的94.3亿美元成长到2030年的140.7亿美元；预计2022年至2030年复合年增长率为5.13%。

子宫颈癌是指发生在子宫颈细胞（即连接阴道的子宫下部）的癌症。 90%的子宫颈恶性肿瘤是由于HPV感染引起的，并透过抹片筛检确诊。子宫颈癌盛行率的增加和HPV感染的增加是推动子宫颈癌治疗市场成长的关键因素。然而，对诊断和治疗方法缺乏认识阻碍了市场的成长。子宫颈癌治疗市场趋势包括主要参与者在子宫颈癌诊断和子宫颈癌治疗药物方面的强劲研发。

子宫颈癌盛行率的增加推动了子宫颈癌治疗市场的成长。

癌症已成为全球主要死亡原因。根据世界卫生组织（WHO）的资料，2019年，癌症是全球183个国家70岁以下人口的第一大死因，也是全球123个国家的第四大死因。卫生组织2021 年3 月称，2020 年约有1,000 万人因不同癌症类型死亡。正在考虑的市场已显示出显着扩张，这可能与全球女性子宫颈癌发生率上升有关。根据世界卫生组织 (WHO) 统计，子宫颈癌每年夺走超过 27 万名女性的生命。由于子宫颈癌发现较晚，较贫穷国家的子宫颈癌死亡率较高。由于用于早期发现子宫颈癌的子宫颈癌诊断测试的接受度不断提高，预计该市场将会成长。

子宫颈癌盛行率的不断上升给世界各地的医疗保健系统带来了负担。据国际癌症研究机构 (IARC) 称，到 2040 年，全球新发癌症病例负担预计将达到约 2,750 万例，到该年该疾病可能会导致约 1.63 亿人死亡。生活方式的改变、吸烟、体力活动减少以及不确定的健康和气候条件等因素可能会在未来几年给世界带来更大的癌症负担。因此，控制和预防全球范围内不断增加的癌症至关重要。

各国政府已启动了加强癌症治疗和预防措施的计画和措施。例如，2017 年，世界卫生大会批准了癌症决议 (WHA70.12)，这是预防和控制癌症的综合方法。该计画一直呼吁世界卫生组织和各国政府加紧努力，实现《预防和控制非传染性疾病（NCD）全球行动计画（2013-2020）》以及《2030 年联合国永续发展目标》中规定的目标。癌症早期死亡的永续发展议程。此外，各种民间组织也加入了防止癌症负担日益增加的行动计划，这产生了对更好的疾病预防措施的需求。因此，子宫颈癌盛行率的不断上升加速了对新有效治疗方法（例如新抗原）的需求，从而推动了市场的成长。

人口、医疗保健提供者和政策制定者对子宫颈癌缺乏认识，获得高品质医疗保健服务和子宫颈筛检计划的机会有限，以及缺乏功能性转诊系统是导致子宫颈癌高发病率和死亡率的因素。由于细胞学筛检和早期子宫颈病变快速治疗的普及，工业化国家的子宫颈癌发病率和死亡率有所下降。实施基于人群的子宫颈筛检并提高低收入和中等收入国家 (LMIC) 的接受度对于降低子宫颈癌死亡率至关重要。提高对危险因子的认识，例如年轻时第一次性交和多位男性性伴侣；与 HPV 8、9 和 10 型相关的高风险；年轻时第一次足月怀孕；长期使用口服避孕药；爱滋病毒感染可能有助于提高筛检计画的参与度。更了解子宫颈癌的症状，如经间期阴道出血、停经后阴道出血、性交后阴道出血、阴道分泌物恶臭和下腹疼痛，可能有助于女性儘早寻求帮助。然而，人们对子宫颈癌缺乏认识阻碍了子宫颈癌治疗市场的成长。

子宫颈癌治疗市场分析是根据类型、产品和最终用户考虑以下细分市场进行的。依类型，市场分为鳞状细胞癌、腺鳞癌和腺癌。根据产品，市场分为手术、放射治疗、化疗、免疫疗法和治疗性疫苗。依最终用户划分，市场分为医院、家庭护理、癌症中心等。子宫颈癌治疗市场报告的地理范围包括北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲、韩国和亚太其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲的其他地区）。 2022年，北美占据最大的子宫颈癌治疗市场。

根据地理位置，子宫颈癌治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。

2022年，北美在子宫颈癌治疗市场中占据最大份额，其中美国占据了很大的市场份额。大量的研发活动主要推动了该国市场的成长；政府、其他私营和非私营组织的财政援助、製药和技术公司内部的合作以及该国神经系统疾病的盛行率不断上升。此外，政府组织在加强测试程序方面的积极参与预计将在预测期内提振市场。此外，罕见疾病监管政策的实施可能为预测期内的市场成长提供重大机会。例如，美国癌症协会（ACS）于2020年9月更新了子宫颈癌筛检指南。因此，这种积极参与的组织预计将支持市场成长。此外，透过识别和评估不同地区市场的主要参与者来进行子宫颈癌治疗市场分析。癌治疗市场报告。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：子宫颈癌治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：子宫颈癌治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：子宫颈癌治疗市场 - 全球市场分析

  • 子宫颈癌治疗 - 全球市场概览
  • 子宫颈癌治疗 - 全球市场与 2030 年预测

第 7 章：子宫颈癌治疗市场 - 收入分析 - 按类型，2020-2030 年

  • 概述
  • 腺癌
  • 腺鳞癌
  • 鳞状细胞癌

第 8 章：子宫颈癌治疗市场 - 收入分析 - 按产品，2020-2030 年

  • 概述
  • 加卫苗/加卫苗 9
  • 子宫颈癌
  • 阿瓦斯丁
  • 可瑞达
  • 其他的

第 9 章：子宫颈癌治疗市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：子宫颈癌治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：子宫颈癌治疗市场 - 主要公司概况

  • F. Hoffmann-La Roche Ltd
  • Merck Sharp and Dohme Corp.
  • GlaxoSmithKline plc.
  • Genentech, Inc.
  • Amgen Inc.
  • Advaxis, Inc.
  • Biocon
  • Allergan, Inc
  • Pfizer Inc
  • AstraZeneca

第 14 章：附录

简介目录
Product Code: TIPRE00004058

The cervical cancer treatment market is expected to grow from US$ 9.43 billion in 2022 to US$ 14.07 billion by 2030; it is anticipated to record a CAGR of 5.13% from 2022 to 2030.

Cervical cancer refers to the cancer that occurs in the cells of the cervix i.e. the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening. The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the market's growth. Cervical cancer treatment market trends include the strong R&D from key players for cervical cancer diagnosis and drugs in cervical cancer treatment.

Increasing Prevalence of Cervical Cancer Fuel Cervical Cancer Treatment Market Growth.

Cancer has emerged as a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in people of age below 70 years in 183 countries and the fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer types. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are greater in poorer nations due to the late discovery of the disease. The market is predicted to rise due to the increasing acceptance of cervical cancer diagnostic tests for the early detection of cervical cancer.

The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease is likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to an even greater burden of cancer in the world in the coming years. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.

Various governments have initiated programs and initiatives to increase cancer treatment and preventive measures. For instance 2017, the World Health Assembly approved the Resolution Cancer (WHA70.12), an integrated approach to preventing and controlling cancer. The program has been appealing to the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013-2020) for the prevention and control of noncommunicable diseases (NCDs) as well as in the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, which is creating a demand for better preventive measures against the disease. Thus, the increasing prevalence of cervical cancer has accelerated the demand for new and effective therapeutic approaches, such as neoantigens, which is boosting the growth of the market.

The lack of awareness about cervical cancer among populations, healthcare providers, and policymakers, limited access to high-quality healthcare services and cervical screening programs, and a lack of functional referral systems are among the factors leading to the high incidence and mortality from cervical cancer. Cervical cancer incidence and mortality have lowered in industrialized countries owing to improved access to cytological screening and rapid treatment of early cervical lesions. It is critical to implement population-based cervical screening and increase its acceptance in low- and middle-income countries (LMICs) to reduce cervical cancer mortality. Raising awareness about risk factors such as first sexual intercourse at a young age and having multiple male sexual partners; high risk associated with the HPV types 8, 9, and 10; first full-term pregnancy at a young age; prolonged use of oral contraceptives; and HIV infections may help boost participation in screening programs. Better awareness regarding the symptoms of cervical cancer, such as intermenstrual vaginal bleeding, postmenopausal vaginal bleeding, post-coital vaginal bleeding, foul vaginal discharge, and lower abdomen pain, might help women seek early help. Nevertheless, the lack of awareness about cervical cancer among populations hinders the cervical cancer treatment market growth.

The cervical cancer treatment market analysis has been conducted by considering the following segments based on type, product, and end user. By type, the market is classified into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. Based on product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. By end user, the market is segmented into hospitals, home care, cancer centers, and others. The geographic scope of the cervical cancer treatment market report includes North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest cervical cancer treatment market share.

Based on geography, the cervical cancer treatment market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

North America held the largest share of the cervical cancer treatment market in 2022, In North America, the US holds a significant share of the market. A vast number of R&D activities primarily drives the market's growth in the country; financial aids by governments other private and non-private organizations, collaborations within pharmaceuticals and technology companies, and increasing prevalence of neurological diseases in the country. Additionally, increasing the active participation of the government organizations in enhancing the testing procedures is expected to boost the market during the forecast period. Furthermore, the implementation of regulatory policies for rare diseases is likely to offer a significant opportunity for the market's growth during the forecast period. For instance, the American Cancer Society (ACS) in September 2020 updated the guidelines for cervical cancer screening. Thus such active involvement organization is expected to support the market growth. Furthermore, the cervical cancer treatment market analysis is carried out by identifying and evaluating key players in the market across different regions.Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are key primary and secondary sources referred to while preparing the cervical cancer treatment market report.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Cervical Cancer Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Cervical Cancer Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Cervical Cancer Treatment Market - Global Market Analysis

  • 6.1 Cervical Cancer Treatment - Global Market Overview
  • 6.2 Cervical Cancer Treatment - Global Market and Forecast to 2030

7. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Adenocarcinoma
  • 7.3 Adenosquamous carcinoma
  • 7.4 Squamous cell carcinoma

8. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 8.1 Overview
  • 8.2 Gardasil/Gardasil 9
  • 8.3 Cervarix
  • 8.4 Avastin
  • 8.5 Keytruda
  • 8.6 Others

9. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10. Cervical Cancer Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Cervical Cancer Treatment Market Overview
    • 10.1.2 North America Cervical Cancer Treatment Market Revenue and Forecasts to 2030
    • 10.1.3 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Product
    • 10.1.5 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Cervical Cancer Treatment Market
        • 10.1.6.1.1 United States Cervical Cancer Treatment Market, by Type
        • 10.1.6.1.2 United States Cervical Cancer Treatment Market, by Product
        • 10.1.6.1.3 United States Cervical Cancer Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Cervical Cancer Treatment Market
        • 10.1.6.2.1 Canada Cervical Cancer Treatment Market, by Type
        • 10.1.6.2.2 Canada Cervical Cancer Treatment Market, by Product
        • 10.1.6.2.3 Canada Cervical Cancer Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Cervical Cancer Treatment Market
        • 10.1.6.3.1 Mexico Cervical Cancer Treatment Market, by Type
        • 10.1.6.3.2 Mexico Cervical Cancer Treatment Market, by Product
        • 10.1.6.3.3 Mexico Cervical Cancer Treatment Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Cervical Cancer Treatment Market - Key Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Merck Sharp and Dohme Corp.
  • 13.3 GlaxoSmithKline plc.
  • 13.4 Genentech, Inc.
  • 13.5 Amgen Inc.
  • 13.6 Advaxis, Inc.
  • 13.7 Biocon
  • 13.8 Allergan, Inc
  • 13.9 Pfizer Inc
  • 13.10 AstraZeneca

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud